Post by pmikeks on Jan 26, 2015 14:39:52 GMT -5
I contacted Blue Cross and Blue Shield of Tennessee and they informed me that Afrezza was not covered but that I could request the Pharmaceutical Board review the drug and request coverage. Below is the letter I sent.
I was unable to print this from Word here at home, it seems it requires a Doctorate degree to get the MFer to print. If you would print this out from Blue Cross down and bring it home with you.
Thanks, Love you
Blue Cross Blue Shield of Tennessee
1 Cameron Hill Cir
Chattanooga Tn. 37402
Atten: Pharmaceutical Management – Dr. White
Dear Dr. White:
I’m writing to request that you and the Pharmaceutical Board review the virtues of a newly on the market drug Afrezza developed by Al Mann’s Mankind and being distributed by SNY. The drug is a rapid acting inhaled insulin taken at meal time that parallels the time frame of an individual’s pancreas. It is superior in every way to the failed Pfizer drug Exubera in that being an inhalable insulin is the only thing they have in common. Afrezza is distributed through a small device similar to an asthma inhaler and because it enters and exits the body rapidly, it virtually eliminates Hypo’s that require visits to the Emergency room. People can take their required insulin as they are supposed therefore helping to reduce future complications.
Like many T2 diabetics, I hate needles and I resisted taking insulin for several years but now I am required to take Lantus Solostar. The monthly cost of Lantus is approx. $326 at Walmart pre-insurance and while I don’t know what Walmart will be charging for Afrezza, an individual in Southern California paid $276 for a month’s supply.
I sincerely hope you will do a little research on this drug and approve it for coverage in the very near future. SNY reps have just completed training (Jan 23-24th) therefore demand will probably be slow initially until word spreads of good control of A1C without needles or hypos, then I’m confident you will see many requests.
Best Regards
I was unable to print this from Word here at home, it seems it requires a Doctorate degree to get the MFer to print. If you would print this out from Blue Cross down and bring it home with you.
Thanks, Love you
Blue Cross Blue Shield of Tennessee
1 Cameron Hill Cir
Chattanooga Tn. 37402
Atten: Pharmaceutical Management – Dr. White
Dear Dr. White:
I’m writing to request that you and the Pharmaceutical Board review the virtues of a newly on the market drug Afrezza developed by Al Mann’s Mankind and being distributed by SNY. The drug is a rapid acting inhaled insulin taken at meal time that parallels the time frame of an individual’s pancreas. It is superior in every way to the failed Pfizer drug Exubera in that being an inhalable insulin is the only thing they have in common. Afrezza is distributed through a small device similar to an asthma inhaler and because it enters and exits the body rapidly, it virtually eliminates Hypo’s that require visits to the Emergency room. People can take their required insulin as they are supposed therefore helping to reduce future complications.
Like many T2 diabetics, I hate needles and I resisted taking insulin for several years but now I am required to take Lantus Solostar. The monthly cost of Lantus is approx. $326 at Walmart pre-insurance and while I don’t know what Walmart will be charging for Afrezza, an individual in Southern California paid $276 for a month’s supply.
I sincerely hope you will do a little research on this drug and approve it for coverage in the very near future. SNY reps have just completed training (Jan 23-24th) therefore demand will probably be slow initially until word spreads of good control of A1C without needles or hypos, then I’m confident you will see many requests.
Best Regards
